KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Cash from Investing Activities (2018 - 2025)

Castle Biosciences' Cash from Investing Activities history spans 7 years, with the latest figure at $8.8 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 53.05% year-over-year to $8.8 million; the TTM value through Dec 2025 reached -$60.4 million, down 20.4%, while the annual FY2025 figure was -$60.4 million, 20.4% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was $8.8 million at Castle Biosciences, up from -$18.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $16.6 million in Q1 2023 and bottomed at -$134.2 million in Q3 2022.
  • The 5-year median for Cash from Investing Activities is -$15.1 million (2023), against an average of -$18.0 million.
  • The largest annual shift saw Cash from Investing Activities crashed 14434.13% in 2022 before it surged 4225.37% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at -$30.9 million in 2021, then surged by 85.49% to -$4.5 million in 2022, then tumbled by 71.17% to -$7.7 million in 2023, then surged by 175.21% to $5.8 million in 2024, then soared by 53.05% to $8.8 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Cash from Investing Activities are $8.8 million (Q4 2025), -$18.4 million (Q3 2025), and -$28.4 million (Q2 2025).